HeartGenetics is a Portuguese biotech company that developed "solutions in a box”, including genetic tests and computational tools designed to support clinical diagnosis and the prevention of cardiovascular diseases.
HeartGenetics is an active portfolio company of ISTART I, AVP Inovação e Internacionalização and AVP III.
- 04/10/2016 HeartGenetics finalist of the @EITHealth #InnoStars GoEurope 2016 Awards: https://t.co/Kithqpzdyd https://t.co/UE6Tjloaev
- 04/10/2016 HeartGenetics with CHUC , has developed the DNArterialDECODER P2020 project: https://t.co/AmRlJgIRn4 https://t.co/k73KnApX1K
- 04/10/2016 HeartGenetics P2020 project, Forward2Future, promotes an increase in the company’s competitiveness and flexibility… https://t.co/bBp4NBuyhk
- 04/10/2016 HeartGenetics announces its new partnership with Umut Biotech, the new distributor in Turkey:… https://t.co/cfWMlGFe3n
- 04/10/2016 It is with great pleasure that we present the new HeartGenetics’ report for Hereditary Thrombophilia (TromboGene™)… https://t.co/b1lUCB6Igk
- 04/10/2016 HeartGenetics, along IPO Porto, started the P2020 research project OncoAlvo, for Cancer Therapy Personalization:… https://t.co/H7LhBrM4lg
- 04/10/2016 Beatriz Godinho Laboratories is the most recent HeartGenetics partner: https://t.co/D5aU07rYr7 https://t.co/pfyp7zXILf
- 04/10/2016 HeartGenetics announces that was selected as one of the 8 companies participating in the EIT GoGlobal DigiHealth:… https://t.co/GE8LLqmTCp
- 04/10/2016 HeartGenetics is proud to announce Pronacera Therapeutics as the first Spanish partner:https://t.co/krxwVSoCAV https://t.co/G0zzrfljNH